Summary of Key Points Core Viewpoint - United Imaging Healthcare (联影医疗) has experienced a decline in stock price, closing at 134.16 CNY as of June 6, 2025, down 2.38% from the previous week, indicating market volatility and investor sentiment [1]. Company Performance - The stock reached a peak price of 143.9 CNY on June 3, 2025, and a low of 133.33 CNY on June 6, 2025 [1]. - The current total market capitalization of United Imaging Healthcare is 110.569 billion CNY, ranking 2nd out of 126 in the medical device sector and 123rd out of 5148 in the A-share market [1]. Upcoming Events - The company will hold its 2024 Annual General Meeting on June 30, 2025, in Shanghai, with both in-person and online voting options available [1]. - Key agenda items for the meeting include the review of the 2024 Board of Directors' report, financial statements, profit distribution plan, and the appointment of auditors [1]. - The record date for shareholders to attend the meeting is set for June 25, 2025, with a registration deadline for in-person attendance on June 27, 2025 [1].

Core Viewpoint - The China Securities Index for the Yangtze River Delta Innovation Index has shown mixed performance, with a slight decline on the latest trading day, reflecting the overall performance of technology companies in the region [1] Group 1: Index Performance - The China Securities Index for the Yangtze River Delta Innovation Index closed down 0.05% at 1822.5 points, with a trading volume of 31.253 billion yuan [1] - Over the past month, the index has increased by 3.20%, while it has decreased by 5.33% over the past three months and is down 0.93% year-to-date [1] Group 2: Index Composition - The index comprises 100 technology companies from the Yangtze River Delta region, selected based on strong R&D investment, profitability, and growth potential [1] - The top ten holdings in the index include: - Lanke Technology (6.44%) - Hikvision (4.83%) - Guodian NARI (4.75%) - Zhongwei Company (4.45%) - United Imaging (4.23%) - Hushan Electronics (3.63%) - Siyuan Electric (3.47%) - Hengsheng Electronics (3.12%) - Xinhengcheng (2.58%) - Tianfu Communication (2.3%) [1] Group 3: Market Sector Distribution - The market sector distribution of the index holdings is as follows: - Information Technology: 43.30% - Industrial: 28.45% - Healthcare: 16.07% - Communication Services: 6.62% - Consumer Discretionary: 4.08% - Materials: 1.48% [2] Group 4: Sample Adjustment - The sample of the index is adjusted semi-annually, with adjustments occurring on the next trading day after the second Friday of June and December each year [2] - Weight factors are adjusted in accordance with the sample changes, and special circumstances may lead to temporary adjustments [2]

Investment Rating - The report does not explicitly state an investment rating for the XR equipment industry Core Insights - The XR equipment industry is experiencing significant growth driven by technological advancements, policy support for domestic alternatives, and increasing demand in the healthcare sector. The market is expected to expand due to factors such as the aging population, rising cardiovascular disease rates, and the implementation of new healthcare policies [4][20][32]. Summary by Sections Industry Definition - XR equipment utilizes X-rays to obtain internal imaging information based on the differential absorption and attenuation of X-rays by various tissues. It is widely used in medical diagnostics, security, and industrial applications, with a focus on medical health in this report [5]. Industry Characteristics - The XR equipment industry is characterized by: - **Technology-Intensive and Innovation-Driven**: The industry relies heavily on technological innovation, particularly in digitalization, AI integration, and low-dose imaging technologies [10]. - **Policy-Driven and Accelerated Domestic Replacement**: Government policies are significantly influencing the market, promoting the use of domestic medical devices [12]. - **Diverse Application Scenarios and Market Segmentation**: XR equipment applications extend beyond traditional medical diagnostics to include industrial inspection and security [13]. Development History - The development of XR equipment in China has gone through three phases: initial reliance on foreign technology, a period of domestic growth supported by policy, and a current phase of technological breakthroughs and international market expansion [14]. Industry Chain Analysis - The XR equipment industry chain includes: - **Upstream**: Comprising core component manufacturing such as chips and sensors, with low domestic production rates [17]. - **Midstream**: Focused on the assembly of devices and content development, with a notable shift towards domestic production [19]. - **Downstream**: Concentrated on application promotion and sales across various sectors, with hospitals being the primary customers [29]. Market Size and Growth - The XR equipment market size is projected to grow from 11.2 billion RMB in 2019 to 14.51 billion RMB in 2024, with a compound annual growth rate (CAGR) of 5.31% [33]. The market is expected to continue expanding due to increasing healthcare demands and supportive policies [36]. Policy Overview - Key policies influencing the XR equipment industry include: - **Equipment Update Policies**: Encouraging medical institutions to upgrade their imaging equipment [41]. - **Support for Domestic Production**: Policies aimed at promoting the use of domestic medical devices [42]. Competitive Landscape - The XR equipment market is dominated by major international players like Siemens, Philips, and GE in the high-end segment, while domestic companies such as United Imaging, Mindray, and Wandong Medical are gaining traction in the mid to low-end markets [44]. The competition is characterized by a clear segmentation based on hospital tiers and equipment preferences [45]. Future Outlook - The XR equipment industry is poised for growth driven by technological advancements, policy support for domestic manufacturers, and increasing healthcare needs, particularly in the context of an aging population and rising chronic disease prevalence [40][46].

Core Viewpoint - The article emphasizes the importance of a comprehensive understanding of the medical and health ecosystem, highlighting the need for entrepreneurs to develop strategic thinking and innovative capabilities to navigate the complexities of the industry [4][11]. Group 1: Program Overview - The program aims to cultivate leadership talents in the medical and health sector by providing a robust academic support system, innovative platforms, and clinical transformation resources [6][9]. - It features a unique value engine methodology that focuses on collaborative efforts between academia and industry to enhance strategic vision and innovation capabilities [7][8]. Group 2: Course Benefits - The curriculum addresses trends, challenges, and innovations in the medical industry, helping participants understand the development trajectory and future direction of the sector [11]. - It explores how to create a strategic execution path tailored to the specific circumstances of enterprises, enabling them to identify opportunities and mitigate risks in complex environments [12][13]. Group 3: Curriculum Modules - The program includes modules on entrepreneurial thinking in uncertain times, macroeconomic growth logic, and strategic diagnosis and execution [16]. - It covers topics such as value discovery, business model design, and investment and merger decision-making in the healthcare sector [17]. Group 4: Alumni and Networking Opportunities - The program facilitates connections between scientists and entrepreneurs through annual conferences and numerous networking events, enhancing collaboration and resource sharing [20][21]. - It offers international study opportunities at prestigious institutions, fostering a global perspective on healthcare innovation [22][23].

Investment Rating - The report indicates a positive investment outlook for the XR equipment industry, driven by technological advancements and policy support for domestic manufacturers [4][11][41]. Core Insights - XR devices are essential in medical diagnostics, particularly for cardiovascular diseases, and are expected to evolve towards smart, low-dose, and high-precision technologies [4][5][9]. - The market for XR devices is projected to grow significantly due to increasing demand from grassroots medical institutions and the aging population [4][31][40]. - Domestic manufacturers are gaining market share due to favorable policies promoting local production and innovation [11][19][45]. Summary by Sections Industry Overview - XR devices are widely used in medical, security, and industrial fields, with a strong emphasis on medical applications for diagnosing various diseases [5][9]. - The industry is characterized by high technological intensity and innovation, with a focus on digitalization and AI integration [9][19]. Market Dynamics - The XR equipment market is expected to grow from 112 billion RMB in 2019 to 145.1 billion RMB by 2024, with a compound annual growth rate (CAGR) of 5.31% [33]. - The demand for XR devices is driven by policies that enhance the capabilities of grassroots medical services and the increasing prevalence of cardiovascular diseases [37][40]. Competitive Landscape - The market is dominated by international brands like Siemens, Philips, and GE in the high-end segment, while domestic brands such as United Imaging and Wandong Medical are gaining traction in the mid to low-end markets [45][46]. - The competitive dynamics are influenced by the differing needs of hospitals at various levels, with tertiary hospitals favoring high-end imported devices and secondary hospitals leaning towards cost-effective domestic options [46]. Policy Impact - Government policies are significantly influencing the XR equipment market, with initiatives aimed at promoting domestic production and upgrading medical equipment in grassroots healthcare settings [11][41][42]. - The "14th Five-Year Plan" for medical equipment development aims to enhance the technological capabilities and quality of medical devices, further supporting the growth of the XR equipment industry [41][42].

证券代码：688271 证券简称：联影医疗 公告编号：2025-017 上海联影医疗科技股份有限公司 关于召开2024年年度股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 股东会召开日期：2025年6月30日 ? 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 一、 召开会议的基本情况 （一） 股东会类型和届次 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 （四） 现场会议召开的日期、时间和地点 本次股东会审议议案及投票股东类型 投票股东类型 序号 议案名称 A 股股东 召开日期时间：2025 年 6 月 30 日 14 点 00 分 召开地点：上海市嘉定区城北路 2258 号一楼 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 6 月 30 日至2025 年 6 月 30 日采用上海证券 交易所网络投票系统，通过交易系统投票平台的投 ...

证券代码：688271 证券简称：联影医疗 公告编号：2025-017 上海联影医疗科技股份有限公司 关于召开2024年年度股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （四） 现场会议召开的日期、时间和地点 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2024年年度股东会 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所科创板上市公司自律监管指引第 1 号 — 规范运作》 等有关规定执行。 二、 会议审议事项 本次股东会审议议案及投票股东类型 | 序号 | 议案名称 | 投票股东类型 | | --- | --- | --- | | | | 股股东 A | | | 非累积投票议案 | | | 1 | 关于公司 2024 年度董事会工作报告的议案 | √ | | 2 | 关于公司 2024 年度监事会工作报告的议案 | √ | | 3 ...

6 月 ETF 调仓主要影响哪些行业和公司？20250605 ETF 调仓对股价的影响是什么？ 根据从 2021 年以来的八次指数调整观察，ETF 调仓对股价影响分为两个阶段。 第一阶段是从调整公告日到调整生效日。在这一段时间内，被动流入规模较大 的公司，其股价正向冲击显著，超额收益更明显。例如，流入规模占最近 10 个交易日成交量比例较高的公司，其超额收益大于 300%的达到 4.7%，200%到 300%的达到 2.52%。负向冲击较大的公司则在这一段时间 内超额收益较低。第二阶段是指数正式生效后，例如今年 6 月 16 日之后，这 一时期资金被动调仓对股价影响不再显著。数据显示，在正式生效后的五个交 易日内，正向影响系数前 30 名公司的平均净值收益不如公告日至生效日期间 显著，而负向冲击公司的净值走势也显示出类似规律。 摘要 主流宽基指数 6 月 16 日进行年终调整，成分调整信息 6 月 3 日发布， 预计将对个股和行业资金流动产生显著影响。 电子、银行、非银金融、机械、有色等行业预计迎来较大规模被动资金 流入，而电力设备、汽车、医药、食品饮料、化工等行业可能面临被动 资金流出。 半导体产业链、农商 ...

Core Viewpoint - The China Securities Index for Healthcare Equipment and Services has shown a mixed performance, with a recent decline despite a slight year-to-date increase, indicating volatility in the healthcare sector [1]. Group 1: Index Performance - The CSI Healthcare Equipment and Services Index decreased by 0.29% to 13723.04 points, with a trading volume of 15.888 billion yuan [1]. - Over the past month, the index has increased by 5.01%, but it has decreased by 3.91% over the last three months, and it has risen by 0.54% year-to-date [1]. Group 2: Index Composition - The index is composed of listed companies in the healthcare sector, reflecting the overall performance of these companies [1]. - The top ten weighted companies in the index include Mindray Medical (9.76%), Aier Eye Hospital (7.89%), and United Imaging Healthcare (7.59%) [1]. - The index is primarily composed of companies listed on the Shenzhen Stock Exchange (60.77%) and the Shanghai Stock Exchange (39.23%) [1]. Group 3: Sample Adjustment and Fund Tracking - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December [2]. - Public funds tracking the healthcare index include several funds from Southern Asset Management and Tianhong Asset Management, among others [2].

Industry Overview - Innovative medical devices refer to new medical equipment with core technology patents, internationally leading technology levels, and significant clinical application value, such as AI-assisted diagnostic devices, 3D-printed implants, and gene testing instruments [2][5] - The development process for innovative medical devices in China typically takes about 5-8 years, including R&D, clinical trials, and regulatory approval [2] - The number of approved innovative medical devices in China has been increasing, with 65 approved in 2024 and 34 in the first four months of 2025 [1][5] Market Status - The medical device industry is a crucial pillar of the modern healthcare system, with significant strategic importance and growth potential [5] - The Chinese government has implemented various policies to encourage innovation and the domestic production of high-end medical devices, leading to rapid industry development [5][7] Enterprise Landscape - The competitive landscape of the innovative medical device industry in China is still in the R&D investment phase, resulting in a low market concentration with over 200 approved production enterprises [11] - Leading companies in the innovative medical device sector include Beijing Pinchi Medical Equipment Co., Ltd., Shenzhen Xianjian Technology Co., Ltd., and Shanghai United Imaging Healthcare Co., Ltd., among others [12][11] Future Trends - The integration of artificial intelligence and the Internet of Things is accelerating in the medical device field, enhancing diagnostic efficiency and accuracy [16] - Domestic companies are rapidly advancing in high-end medical equipment and consumables, with increasing market share for products like vascular stents and artificial joints [17] - Chinese innovative medical device companies are actively expanding into overseas markets through technology licensing and cross-border cooperation [18]